Stockscreener 앱 받기
32.04
0.22%
-0.07
시간 외 거래:
32.04
전일 마감가:
$32.11
열려 있는:
$31.72
하루 거래량:
1.13M
Relative Volume:
0.93
시가총액:
$6.62B
수익:
-
순이익/손실:
$-505.61M
주가수익비율:
-11.57
EPS:
-2.7697
순현금흐름:
$-407.32M
1주 성능:
-5.15%
1개월 성능:
-18.37%
6개월 성능:
+30.19%
1년 성능:
+98.88%
1일 변동 폭
$31.58
$32.75
1주일 범위
$31.36
$34.60
52주 변동 폭
$16.04
$45.42
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
32.04 | 6.88B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant, Inc. (IMVT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next - Yahoo Finance
Sjogren’s Syndrome Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 – DelveInsight | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherap - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Immunovant (IMVT) Just Gave Investors Something To Think About - Yahoo Finance
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case - Yahoo Finance
HanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritis - finance.biggo.com
Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $37 - Moomoo
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media
Immunovant, Inc. Investigation Initiated: Levi & Korsinsky Investigates The Officers and Directors of Immunovant, Inc. (IMVT) - ACCESS Newswire
Immunovant, Inc. (IMVT) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
IMVT Investor Alert: Levi & Korsinsky Investigates Immunovant, Inc. (IMVT) For Potential Securities Fraud - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Immunovant shares drop 6% after lupus drug stud... - Pluang
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) - PR Newswire
IMVT SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Immunovant, Inc. For Possible Securities Law Violations - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Experimental skin lupus therapy dropped after trial misses main goal - Lupus News Today
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - Yahoo Finance
Lilly’s latest China drug deal; Immunovant’s setback in lupus - Yahoo Finance
Immunovant stock rating maintained at Buy by H.C. Wainwright - Investing.com Canada
Roivant reports top-line data from IMVT-1402 CLE trial - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $53 - Moomoo
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Immunovant stock falls 6.02 percent after lupus trial miss - AD HOC NEWS
Immunovant Scraps Lupus Skin Treatment After Midstage Trial Falls Short - finance.biggo.com
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program - Barron's
Why is Immunovant stock sliding today? By Investing.com - Investing.com Canada
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss - Mugglehead Investment Magazine
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Immunovant ends cutaneous lupus program after phase 2 flop - Fierce Biotech
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Yahoo Finance
Immunovant Shares Down 6.7% Premarket After C - moomoo.com
Immunovant stock falls after lupus drug trial misses goal By Investing.com - Investing.com Canada
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint - Yahoo Finance
Trial miss for Immunovant’s study of IMVT-1402 in CLE - The Pharma Letter
Immunovant halts lupus drug development after trial miss - Investing.com
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
Immunovant halts lupus drug development after trial miss By Investing.com - Investing.com Canada
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - The Manila Times
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Kuehn Law investigates Immunovant over potential fiduciary breaches - scanx.trade
Immunovant stock edges lower after recent clinical pipeline focus - AD HOC NEWS
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - Eastern Progress
Immunovant stock holds gains as investors eye upcoming data and recent revenue growth - AD HOC NEWS
Immunovant Q1FY27 Results: $950m Moderna settlement boosts cash - scanx.trade
Immunovant Q1 2027 Earnings Call: Complete Transcript - Benzinga
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36? - Yahoo Finance
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venker Eric | Chief Executive Officer |
Oct 02 '26 |
Sale |
34.11 |
3,506 |
119,590 |
257,075 |
| Van Tuyl Christopher | Chief Legal Officer |
Sep 23 '26 |
Sale |
36.36 |
2,846 |
103,481 |
176,545 |
| Pande Atul | Director |
Aug 28 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Aug 28 '26 |
Sale |
43.27 |
1,500 |
64,905 |
116,731 |
| Gloria Melanie | Chief Operating Officer |
Aug 20 '26 |
Sale |
44.16 |
3,056 |
134,953 |
219,301 |
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
| Girao Tiago | Chief Financial Officer |
Jul 23 '26 |
Sale |
38.69 |
6,798 |
263,015 |
240,798 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '26 |
Sale |
38.69 |
2,857 |
110,537 |
205,341 |
| Gloria Melanie | Chief Operating Officer |
Jul 08 '26 |
Sale |
39.55 |
2,036 |
80,532 |
222,357 |
0.50%
0.57%
자본화:
|
볼륨(24시간):